person · Reporting owner

CLARK IAN T

Disclosed activity across 12 companies

Tapewire entity: 26178
SEC CIK: 0001336504

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499	Director	May 20, 2022	May 24, 2022
BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404	Director	June 02, 2026	June 04, 2026
Corvus Pharmaceuticals, Inc.CRVS · Entity 4839	Director	June 11, 2026	June 15, 2026
GoodRx Holdings, Inc.GDRX · Entity 4838	Director	July 08, 2025	July 09, 2025
Guardant Health, Inc.GH · Entity 3238	Director	August 04, 2026	August 05, 2026
Kyverna Therapeutics, Inc.KYTX · Entity 5452	Director	May 27, 2026	May 29, 2026
Olema Pharmaceuticals, Inc.OLMA · Entity 613	Director	June 18, 2026	June 23, 2026
TAKEDA PHARMACEUTICAL CO LTDTAK · Entity 2662	Director	March 18, 2026	March 18, 2026
Tectonic Therapeutic, Inc.AVRO · Entity 5328	Director	June 06, 2023	June 08, 2023
TerraVia Holdings, Inc.TVIA · Entity 175855	Director	May 22, 2017	May 23, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AGIOS PHARMACEUTICALS, INC.

Report date May 20, 2022 · Filed May 24, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	6,549	Reported balance After 2022-05-20 transaction · row 1 1 source row Row 1 · 2022-05-20 · Exercise / conversion · Acquired 1,585 · Balance 6,549
Restricted stock unitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-05-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-05-20 · Exercise / conversion · Disposed 1,585 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested

BIOMARIN PHARMACEUTICAL INC

Report date June 02, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	14,490	Reported balance After 2026-06-02 transaction · row 1 1 source row Row 1 · 2026-06-02 · Grant · Acquired 7,490 · Balance 14,490 F1: Restricted stock units granted on June 2, 2026. Price not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units granted on June 2, 2026. Price not applicable.

Corvus Pharmaceuticals, Inc.

Report date June 11, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.60 · Expires 2036-06-11	Direct	15,000	Reported balance After 2026-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-11 · Grant · Acquired 15,000 · Balance 15,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

GoodRx Holdings, Inc.

Report date July 08, 2025 · Filed July 09, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	100,150	Reported balance After 2025-07-08 transaction · row 1 1 source row Row 1 · 2025-07-08 · Exercise / conversion · Acquired 17,248 · Balance 100,150
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	34,497	Reported balance After 2025-07-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-07-08 · Exercise / conversion · Disposed 17,248 · Balance 34,497 F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2: The restricted stock unit award vests as to one-third of the shares underlying the award on each of the first three anniversaries of the grant date, beginning on July 8, 2025, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

F2: The restricted stock unit award vests as to one-third of the shares underlying the award on each of the first three anniversaries of the grant date, beginning on July 8, 2025, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

Guardant Health, Inc.

Report date August 04, 2026 · Filed August 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account	10,322	Reported balance After 2026-08-04 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-08-04 · Exercise / conversion · Acquired 2,255 · Balance 10,322
Common StockSEC Table I · non-derivative	IndirectBy The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account	17,155	Reported balance After 2026-08-04 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-08-04 · Exercise / conversion · Acquired 6,833 · Balance 17,155
Common StockSEC Table I · non-derivative	IndirectBy The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account	8,067	Reported balance After 2026-08-04 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-08-04 · Sale · Disposed 9,088 · Balance 8,067 F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $158.510 to $159.435. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
Common StockSEC Table I · non-derivative	IndirectBy The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account	2,975	Reported balance After 2026-08-04 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2026-08-04 · Sale · Disposed 5,092 · Balance 2,975 F2: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $158.51 to $159.14. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.11 · Expires 2029-06-18	Direct	0	Reported balance After 2026-08-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-08-04 · Exercise / conversion · Disposed 2,255 · Balance 0 F3: The stock option vested in full on June 12, 2020.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.57 · Expires 2035-06-18	Direct	0	Reported balance After 2026-08-04 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-08-04 · Exercise / conversion · Disposed 6,833 · Balance 0 F4: The stock option vested in full on June 17, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $158.510 to $159.435. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F2: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $158.51 to $159.14. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The stock option vested in full on June 12, 2020.

F4: The stock option vested in full on June 17, 2026.

Kyverna Therapeutics, Inc.

Report date May 27, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	21,727	Reported balance After 2026-05-27 transaction · row 1 1 source row Row 1 · 2026-05-27 · Grant · Acquired 5,093 · Balance 21,727 F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.59 · Expires 2036-05-27	Direct	20,582	Reported balance After 2026-05-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-27 · Grant · Acquired 20,582 · Balance 20,582 F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Olema Pharmaceuticals, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.51 · Expires 2036-06-18	Direct	29,500	Reported balance After 2026-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 29,500 · Balance 29,500 F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

TAKEDA PHARMACEUTICAL CO LTD

Report date March 18, 2026 · Filed March 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
American Depositary SharesSEC Table I · non-derivative	Direct	9,696	Reported balance Holding disclosure · report date 2026-03-18 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 9,696
Ordinary SharesSEC Table I · non-derivative	Direct	9,700	Reported balance Holding disclosure · report date 2026-03-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 9,700 F1: Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on the following schedule: June 1, 2026 (3,100 ordinary shares), June 1, 2027 (3,400 ordinary shares) and June 1, 2028 (3,200 ordinary shares).
Tax Obligation AwardSEC Table II · derivative / convertible security · Expires 2026-06-01	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F2: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
Tax Obligation AwardSEC Table II · derivative / convertible security · Expires 2027-06-01	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F2: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
Tax Obligation AwardSEC Table II · derivative / convertible security · Expires 2028-06-01	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F2: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
Cash Settled Retirement AwardSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F3: Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive a cash amount equivalent to the value of one Ordinary Share at the time of vest. The RSUs vest upon the director's retirement from the board.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on the following schedule: June 1, 2026 (3,100 ordinary shares), June 1, 2027 (3,400 ordinary shares) and June 1, 2028 (3,200 ordinary shares).

F2: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.

F3: Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive a cash amount equivalent to the value of one Ordinary Share at the time of vest. The RSUs vest upon the director's retirement from the board.

Tectonic Therapeutic, Inc.

Report date June 06, 2023 · Filed June 08, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2033-06-05	Direct	17,643	Reported balance After 2023-06-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-06 · Grant · Acquired 17,643 · Balance 17,643 F1: The option shall vest in full upon the earlier of June 6, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shall vest in full upon the earlier of June 6, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.

TerraVia Holdings, Inc.

Report date May 22, 2017 · Filed May 23, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2027-05-21	Direct	32,000	Reported balance After 2017-05-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-05-22 · Grant · Acquired 32,000 · Balance 32,000 F1: The option vests as to 1/12 of the underlying shares monthly beginning July 1, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests as to 1/12 of the underlying shares monthly beginning July 1, 2017.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Forty Seven, Inc.

Report date April 07, 2020 · Filed April 07, 2020

Section 16 reporting ended · disclosed 2020-04-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 · Expires 2028-05-02	Direct	0	Reported balance After 2020-04-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-04-07 · Disposition to issuer · Disposed 126,493 · Balance 0 F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger"), upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F2: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning April 28, 2018, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $10,972,319.05, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 · Expires 2029-06-11	Direct	0	Reported balance After 2020-04-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-04-07 · Disposition to issuer · Disposed 10,322 · Balance 0 F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger"), upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F2: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning April 28, 2018, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $10,972,319.05, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F3: This option, which provided for vesting on the one-year anniversary of the grant date, subject to Reporting Person's continuous service on such date, was canceled in the Merger in exchange for a cash payment of $874,170.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger"), upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F2: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning April 28, 2018, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $10,972,319.05, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

F3: This option, which provided for vesting on the one-year anniversary of the grant date, subject to Reporting Person's continuous service on such date, was canceled in the Merger in exchange for a cash payment of $874,170.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

Kite Pharma, Inc.

Report date October 03, 2017 · Filed October 06, 2017

Section 16 reporting ended · disclosed 2017-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2017-10-03 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2017-10-03 · Other · Disposed 1,776 · Balance 5,324 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. Row 2 · 2017-10-03 · Disposition to issuer · Disposed 5,324 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a "Director Restricted Stock Unit"). Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.95 · Expires 2027-01-03	Direct	Reported balance After 2017-10-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-10-03 · Disposition to issuer · Disposed 17,130 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F4: The option provided for vesting in 36 equal monthly installments on the last day of each month following the date of grant, January 3, 2017.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.21 · Expires 2027-06-19	Direct	Reported balance After 2017-10-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-10-03 · Disposition to issuer · Disposed 8,810 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F6: This option provided for vesting in 12 equal monthly installments following June 20, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes.

F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes.

F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a "Director Restricted Stock Unit"). Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit.

F4: The option provided for vesting in 36 equal monthly installments on the last day of each month following the date of grant, January 3, 2017.

F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option.

F6: This option provided for vesting in 12 equal monthly installments following June 20, 2017.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 04, 2019 Filed Nov 7, 2019 01:21 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative	2,690	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0001628280-19-013568 · wf-form4_157308968324681.xml · derivative · entry 3 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,659 Underlying: COMMON STOCK · 2,690 shares Expires 2027-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on January 3, 2017. Read SEC document
November 04, 2019 Filed Nov 7, 2019 01:21 UTC	Guardant Health, Inc. GH · Entity 3238	SaleCOMMON STOCK	2,690	$71.82	$193,195.80	Disclosure SEC source: 0001628280-19-013568 · wf-form4_157308968324681.xml · nonDerivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,302 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. Read SEC document
November 04, 2019 Filed Nov 7, 2019 01:21 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	2,690	$4.18	$11,244.20	Disclosure SEC source: 0001628280-19-013568 · wf-form4_157308968324681.xml · nonDerivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 28, 2019 Filed Oct 30, 2019 00:15 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative	538	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0001628280-19-012709 · wf-form4_157239449897742.xml · derivative · entry 4 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,912 Underlying: COMMON STOCK · 538 shares Expires 2027-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on October 25, 2017. Read SEC document
October 28, 2019 Filed Oct 30, 2019 00:15 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative	2,690	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0001628280-19-012709 · wf-form4_157239449897742.xml · derivative · entry 3 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,349 Underlying: COMMON STOCK · 2,690 shares Expires 2027-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on January 3, 2017. Read SEC document
October 28, 2019 Filed Oct 30, 2019 00:15 UTC	Guardant Health, Inc. GH · Entity 3238	SaleCOMMON STOCK	3,228	$70.00	$225,960.00	Disclosure SEC source: 0001628280-19-012709 · wf-form4_157239449897742.xml · nonDerivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,302 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. Read SEC document
October 28, 2019 Filed Oct 30, 2019 00:15 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	3,228	$4.18	$13,493.04	Disclosure SEC source: 0001628280-19-012709 · wf-form4_157239449897742.xml · nonDerivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 25, 2019 Filed Sep 28, 2019 00:36 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative	538	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0001628280-19-011978 · wf-form4_156963099808325.xml · derivative · entry 3 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,450 Underlying: COMMON STOCK · 538 shares Expires 2027-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on October 25, 2017. Read SEC document
September 25, 2019 Filed Sep 28, 2019 00:36 UTC	Guardant Health, Inc. GH · Entity 3238	SaleCOMMON STOCK	538	$72.00	$38,736.00	Disclosure SEC source: 0001628280-19-011978 · wf-form4_156963099808325.xml · nonDerivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,302 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. Read SEC document
September 25, 2019 Filed Sep 28, 2019 00:36 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	538	$4.18	$2,248.84	Disclosure SEC source: 0001628280-19-011978 · wf-form4_156963099808325.xml · nonDerivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 03, 2019 Filed Sep 5, 2019 20:56 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative	2,690	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0001628280-19-011451 · wf-form4_156771697687018.xml · derivative · entry 3 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,039 Underlying: COMMON STOCK · 2,690 shares Expires 2027-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on January 3, 2017. Read SEC document
September 03, 2019 Filed Sep 5, 2019 20:56 UTC	Guardant Health, Inc. GH · Entity 3238	SaleCOMMON STOCK	2,690	$85.70	$230,533.00	Disclosure SEC source: 0001628280-19-011451 · wf-form4_156771697687018.xml · nonDerivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,302 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. Read SEC document
September 03, 2019 Filed Sep 5, 2019 20:56 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	2,690	$4.18	$11,244.20	Disclosure SEC source: 0001628280-19-011451 · wf-form4_156771697687018.xml · nonDerivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 26, 2019 Filed Aug 28, 2019 21:46 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative	538	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0001628280-19-011256 · wf-form4_156702876964626.xml · derivative · entry 3 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,988 Underlying: COMMON STOCK · 538 shares Expires 2027-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on October 25, 2017. Read SEC document
August 26, 2019 Filed Aug 28, 2019 21:46 UTC	Guardant Health, Inc. GH · Entity 3238	SaleCOMMON STOCK	538	$94.05	$50,598.90	Disclosure SEC source: 0001628280-19-011256 · wf-form4_156702876964626.xml · nonDerivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,302 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. Read SEC document
August 26, 2019 Filed Aug 28, 2019 21:46 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	538	$4.18	$2,248.84	Disclosure SEC source: 0001628280-19-011256 · wf-form4_156702876964626.xml · nonDerivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 06, 2019 Filed Aug 8, 2019 20:53 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative	1,614	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0001628280-19-010481 · wf-form4_156529758863178.xml · derivative · entry 7 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,526 Underlying: COMMON STOCK · 1,614 shares Expires 2027-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on October 25, 2017. Read SEC document
August 06, 2019 Filed Aug 8, 2019 20:53 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative	8,069	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0001628280-19-010481 · wf-form4_156529758863178.xml · derivative · entry 6 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,729 Underlying: COMMON STOCK · 8,069 shares Expires 2027-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on January 3, 2017. F6 · derivative.expiration_date: The expiration date of May 31, 2027 reported in the Reporting Person's prior Form 3 and Form 4 filings was in error. Read SEC document
August 06, 2019 Filed Aug 8, 2019 20:53 UTC	Guardant Health, Inc. GH · Entity 3238	SaleCOMMON STOCK	3,013	$90.30	$272,073.90	Disclosure SEC source: 0001628280-19-010481 · wf-form4_156529758863178.xml · nonDerivative · entry 5 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,302 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.09 to $90.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
August 06, 2019 Filed Aug 8, 2019 20:53 UTC	Guardant Health, Inc. GH · Entity 3238	SaleCOMMON STOCK	5,706	$89.71	$511,885.26	Disclosure SEC source: 0001628280-19-010481 · wf-form4_156529758863178.xml · nonDerivative · entry 4 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,315 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.08 to $90.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
August 06, 2019 Filed Aug 8, 2019 20:53 UTC	Guardant Health, Inc. GH · Entity 3238	SaleCOMMON STOCK	964	$88.30	$85,121.20	Disclosure SEC source: 0001628280-19-010481 · wf-form4_156529758863178.xml · nonDerivative · entry 3 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,021 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
August 06, 2019 Filed Aug 8, 2019 20:53 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	1,614	$4.18	$6,746.52	Disclosure SEC source: 0001628280-19-010481 · wf-form4_156529758863178.xml · nonDerivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 06, 2019 Filed Aug 8, 2019 20:53 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	8,069	$4.18	$33,728.42	Disclosure SEC source: 0001628280-19-010481 · wf-form4_156529758863178.xml · nonDerivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 20, 2019 Filed Jun 24, 2019 20:05 UTC	Corvus Pharmaceuticals, Inc. CRVS · Entity 4839	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $3.61	$0.00	Disclosure SEC source: 0000899243-19-017913 · doc4.xml · derivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-20 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document
June 18, 2019 Filed Jun 20, 2019 22:10 UTC	Guardant Health, Inc. GH · Entity 3238	GrantSTOCK OPTION (RIGHT TO BUY) · Derivative	2,255	$0.00 Strike: $91.11	$0.00	Disclosure SEC source: 0001628280-19-008202 · wf-form4_156106859466285.xml · derivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,255 Underlying: COMMON STOCK · 2,255 shares Expires 2029-06-17 F1 · derivative.exercise_date: The stock option vests in full on the earlier to occur of (i) June 18, 2020 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document
June 18, 2019 Filed Jun 20, 2019 22:10 UTC	Guardant Health, Inc. GH · Entity 3238	GrantCOMMON STOCK	1,302	$0.00	$0.00	Disclosure SEC source: 0001628280-19-008202 · wf-form4_156106859466285.xml · nonDerivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,302 Read SEC document
June 12, 2019 Filed Jun 14, 2019 18:10 UTC	Forty Seven, Inc. FTSV · Entity 16035	GrantStock Option (right to buy) · Derivative	10,322	$0.00 Strike: $10.81	$0.00	Disclosure SEC source: 0001209191-19-037266 · doc4.xml · derivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,322 Underlying: Common Stock · 10,322 shares Expires 2029-06-11 F1 · derivative.exercise_date: The shares subject to the option vest on the one-year anniversary of the grant date, subject to Reporting Person's continuous service on such date. Read SEC document
June 11, 2019 Filed Jun 13, 2019 21:09 UTC	Tectonic Therapeutic, Inc. AVRO · Entity 5328	GrantStock Option (Right to Buy) · Derivative	9,675	$0.00 Strike: $13.60	$0.00	Disclosure SEC source: 0000899243-19-016856 · doc4.xml · derivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,675 Underlying: Common Stock · 9,675 shares Expires 2029-06-10 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document
May 31, 2019 Filed May 31, 2019 20:04 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock units · Derivative	1,400	$0.00	$0.00	Disclosure SEC source: 0001209191-19-033616 · doc4.xml · derivative · entry 4 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
May 31, 2019 Filed May 31, 2019 20:04 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	1,400	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-033616 · doc4.xml · nonDerivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document
May 29, 2019 Filed May 31, 2019 20:04 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock units · Derivative	1,878	$0.00	$0.00	Disclosure SEC source: 0001209191-19-033616 · doc4.xml · derivative · entry 3 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,878 Underlying: Common stock · 1,878 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
May 29, 2019 Filed May 31, 2019 20:04 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock option (right to buy) · Derivative	8,919	$0.00 Strike: $47.91	$0.00	Disclosure SEC source: 0001209191-19-033616 · doc4.xml · derivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,919 Underlying: Common stock · 8,919 shares Expires 2029-05-29 F2 · derivative.exercise_date: This option was granted on May 29, 2019. The shares underlying this option vest as to 100% of the underlying shares on May 29, 2020. Read SEC document
May 03, 2019 Filed May 3, 2019 22:05 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative	2,690	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0001628280-19-005842 · wf-form4_155692112718431.xml · derivative · entry 3 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,798 Underlying: COMMON STOCK · 2,690 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on January 3, 2017. Read SEC document
May 03, 2019 Filed May 3, 2019 22:05 UTC	Guardant Health, Inc. GH · Entity 3238	SaleCOMMON STOCK	2,690	$65.91	$177,297.90	Disclosure SEC source: 0001628280-19-005842 · wf-form4_155692112718431.xml · nonDerivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. Read SEC document
May 03, 2019 Filed May 3, 2019 22:05 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	2,690	$4.18	$11,244.20	Disclosure SEC source: 0001628280-19-005842 · wf-form4_155692112718431.xml · nonDerivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 25, 2019 Filed Apr 29, 2019 22:33 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative	538	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0001628280-19-004973 · wf-form4_155657717448512.xml · derivative · entry 3 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,140 Underlying: COMMON STOCK · 538 shares Expires 2027-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on October 25, 2017. Read SEC document
April 25, 2019 Filed Apr 29, 2019 22:33 UTC	Guardant Health, Inc. GH · Entity 3238	SaleCOMMON STOCK	538	$65.11	$35,029.18	Disclosure SEC source: 0001628280-19-004973 · wf-form4_155657717448512.xml · nonDerivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. Read SEC document
April 25, 2019 Filed Apr 29, 2019 22:33 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	538	$4.18	$2,248.84	Disclosure SEC source: 0001628280-19-004973 · wf-form4_155657717448512.xml · nonDerivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 15, 2019 Filed Apr 17, 2019 23:16 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative	9,145	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0001628280-19-004394 · wf-form4_155554295905639.xml · derivative · entry 4 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,678 Underlying: COMMON STOCK · 9,145 shares Expires 2027-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price of $4.17 reported in the Reporting Person's Form 3 filed on October 3, 2018 was in error. F4 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on October 25, 2017. Read SEC document
April 15, 2019 Filed Apr 17, 2019 23:16 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative	72,627	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0001628280-19-004394 · wf-form4_155554295905639.xml · derivative · entry 3 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,488 Underlying: COMMON STOCK · 72,627 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price of $4.17 reported in the Reporting Person's Form 3 filed on October 3, 2018 was in error. F3 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on January 3, 2017. Read SEC document
April 15, 2019 Filed Apr 17, 2019 23:16 UTC	Guardant Health, Inc. GH · Entity 3238	SaleCOMMON STOCK	81,772	$73.90	$6,042,950.80	Disclosure SEC source: 0001628280-19-004394 · wf-form4_155554295905639.xml · nonDerivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. Read SEC document
April 15, 2019 Filed Apr 17, 2019 23:16 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	81,772	$4.18	$341,806.96	Disclosure SEC source: 0001628280-19-004394 · wf-form4_155554295905639.xml · nonDerivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 21, 2018 Filed Jun 25, 2018 20:05 UTC	Corvus Pharmaceuticals, Inc. CRVS · Entity 4839	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $12.50	$0.00	Disclosure SEC source: 0000899243-18-017913 · doc4.xml · derivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document
May 31, 2018 Filed Jun 4, 2018 20:15 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock units · Derivative	1,400	$0.00	$0.00	Disclosure SEC source: 0001209191-18-035033 · doc4.xml · derivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common stock · 1,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
May 31, 2018 Filed Jun 4, 2018 20:15 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock option (right to buy) · Derivative	5,700	$0.00 Strike: $93.50	$0.00	Disclosure SEC source: 0001209191-18-035033 · doc4.xml · derivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common stock · 5,700 shares Expires 2028-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:27 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	8,810	$88.79 Strike: $91.21	$782,239.90	Disclosure SEC source: 0001209191-17-056239 · doc4.xml · derivative · entry 4 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,810 shares Expires 2027-06-19 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5 · price: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F6 · derivative.exercise_date: This option provided for vesting in 12 equal monthly installments following June 20, 2017. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:27 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	17,130	$134.05 Strike: $45.95	$2,296,276.50	Disclosure SEC source: 0001209191-17-056239 · doc4.xml · derivative · entry 3 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,130 shares Expires 2027-01-03 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5 · price: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F4 · derivative.exercise_date: The option provided for vesting in 36 equal monthly installments on the last day of each month following the date of grant, January 3, 2017. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:27 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerCommon Stock	5,324	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-056239 · doc4.xml · nonDerivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F3 · price: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a "Director Restricted Stock Unit"). Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:27 UTC	Kite Pharma, Inc. KITE · Entity 172664	OtherCommon Stock	1,776	$180.00	$319,680.00	Disclosure SEC source: 0001209191-17-056239 · doc4.xml · nonDerivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,324 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. Read SEC document
June 20, 2017 Filed Jun 22, 2017 18:47 UTC	Kite Pharma, Inc. KITE · Entity 172664	GrantDirector Stock Option (Right to Buy) · Derivative	8,810	$0.00 Strike: $91.21	$0.00	Disclosure SEC source: 0001209191-17-041310 · doc4.xml · derivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,810 Underlying: Common Stock · 8,810 shares Expires 2027-06-19 F1 · derivative.exercise_date: The stock option shall vest in 12 successive equal monthly installments following the date of grant. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.